Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus

On January 12, Wedbush analyst Laura Chico lifted the price target on the stock to $95 from $83, citing the company’s recent ...

Needham Analyst Keeps a Buy Rating on Praxis Precision Medicines, Inc. (PRAX)

On January 5, 2026, TheFly reported that Needham analyst Ami Fadia kept a Buy recommendation on Praxis Precision Medicines, ...

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an ...
Nasdaq

Catheter Precision, Inc. Announces Exercise of Warrants for $4.9 Million of Gross Proceeds

FORT MILL, SC / ACCESSWIRE / October 25, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company, today announced the entry into a definitive agreement for ...

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders ...